Endurant Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Endurant Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,180	Closed	-$530K	–	87
2018 Q2	$530K	Sell	7,180 -7,250	-50%	-$565K	0.23%	56
2018 Q1	$947K	Buy	+14,430	New	+$1.09M	0.35%	54
2015 Q1	–	Sell	-2,055	Closed	-$473K	–	107
2014 Q4	$473K	Buy	+2,055	New	+$441K	0.19%	83

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Endurant Capital Management's BLCM Position: Q3 2018 in Review

Endurant Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2018, closing a stake of 7,180 shares — an estimated $530K sold.

Endurant Capital Management first reported a position in BLCM in Q4 2014 and held it in 3 quarters. The position peaked at $947K in Q1 2018. 100 funds tracked by Wall St. Rank hold BLCM as of Q3 2018.

Endurant Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Endurant Capital Management sold 7,180 Bellicum Pharmaceuticals, Inc. shares in Q3 2018, an estimated $530K.
Endurant Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
Endurant Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $947K in Q1 2018.
100 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2018.

Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.